(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 12.93% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.12%.
Repligen's revenue in 2025 is $650,429,000.On average, 6 Wall Street analysts forecast RGEN's revenue for 2025 to be $40,811,965,671, with the lowest RGEN revenue forecast at $40,570,378,341, and the highest RGEN revenue forecast at $41,031,641,592. On average, 6 Wall Street analysts forecast RGEN's revenue for 2026 to be $46,051,713,943, with the lowest RGEN revenue forecast at $44,617,247,034, and the highest RGEN revenue forecast at $47,755,635,000.
In 2027, RGEN is forecast to generate $54,333,552,348 in revenue, with the lowest revenue forecast at $54,333,552,348 and the highest revenue forecast at $54,333,552,348.